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Case report
Pleuroparenchymal sarcoidosis - A recognised but rare manifestation of
disease
S. Walkerb, H. Adamalia, N. Bhatta, N. Maskella,b, S.L. Barratta,b,∗
aNorth Bristol Interstitial Lung Disease Service, Southmead Hospital, Bristol, UK
bAcademic Respiratory Unit, School of Clinical Sciences, University of Bristol, Bristol, UK
A B S T R A C T
Pleural involvement is rare in sarcoidosis. The presence of a large symptomatic eﬀusion in a patient with sar-
coidosis should therefore prompt further investigation for an alternate aetiology. Here we present a case of
conﬁrmed pleuro-parenchymal sarcoidosis. We discuss the important diﬀerential diagnoses and review the
current literature.
1. Case report
A 67-year-old Caucasian non-smoker female with a past medical
history of hypertension and hypothyroidism presented to our clinic
with a 12-month history of exertional dyspnoea and dry cough. She was
otherwise well with no systemic, nasal or gastro-oesophageal symp-
toms. Her prescribed medications were levothyroxine, aspirin and lo-
sartan and these had not changed in recent years. She denied atopy,
exposure to previous TB or recent travel and systems enquiry did not
reveal any eye, genitourinary or gastrointestinal symptoms. She had
worked throughout her career in administration.
Vital signs were recorded as pulse 80 bpm, blood pressure 130/
50mmHg, respiratory rate 17 and oxygen saturations of 97% air.
Cardiorespiratory examination was normal. Lung function revealed:
FEV1 1.14 (57% predicted), FVC 1.60 (67% predicted), FEV1/FVC ratio
71%, TLCO 3.30 (71% predicted), TLCO 5.48 (79% predicted) and KCO
1.95 (131% predicted). ECG showed sinus rhythm with no evidence of
heart block. Chest X-ray showed blunting of the costophrenic angles
with scattered peribronchial thickening predominantly within the mid
and lower zones (Fig. 1a). High resolution computed tomography
(HRCT)-Chest demonstrated bilateral hilar and central mediastinal
nodal calciﬁcation, in the absence of signiﬁcant lymphadenopathy,
with perilymphatic nodularity in the upper and mid zones of the lungs
and bilateral pleural eﬀusions, left larger than right (Fig. 1bi). Echo-
cardiogram was normal.
Laboratory investigations revealed a mildly elevated ACE level
(summarised in Fig. 2). Left sided chest ultrasound demonstrated an
anechoic eﬀusion, with an exudative lymphocytic yellow aspirate
(lymphocytes 70%), with a normal adenosine deaminase (ADA) level
that was negative to TB culture (summarised in Fig. 2).
Given the suspicion of pulmonary sarcoidosis, ﬂexible bronchoscopy
was undertaken to obtain a tissue diagnosis. Bronchoalveolar lavage
samples demonstrated 90% macrophages and 10% lymphocytes.
Cultures were negative for TB and fungi. Endobronchial biopsies (Fig. 1
ci) demonstrated discrete non-necrotising epithelioid granulomas con-
sistent with sarcoidosis. Transbronchial biopsies were non-diagnostic.
Sarcoidosis was considered the most likely overarching diagnosis
and thus the patient was commenced on a tapering course of oral
prednisolone therapy over the following 9 months. Initial clinical im-
provement was followed by progressive breathlessness. HRCT demon-
strated stable parenchymal appearances but worsening right eﬀusion
(Fig. 1 a and bii). MRI excluded cardiac sarcoidosis, demonstrating mild
diastolic dysfunction only. Attempted diuresis, a repeat trial of tapering
doses of prednisolone then introduction of methotrexate (12.5mg
weekly) in conjunction with prednisolone 10mg had no signiﬁcant
beneﬁt, with gradual worsening of bilateral eﬀusions and symptoms
over the subsequent 12 months (Fig. 1a). In light of this deterioration a
deﬁnitive diagnosis was sought. Medical thoracoscopy was not techni-
cally feasible and thus she proceeded to right-sided video-assisted
thoracoscopic (VATS) wedge lung biopsy and pleural biopsy with
planned therapeutic drainage and talc pleurodesis.
Pleural biopsies showed features of chronic pleuritis with associated
granulomata (Fig. 1c ii-iii). The lung VATS biopsy sections (Fig. 1 c iv)
showed pleural and subpleural granulomatous inﬂammation. A small
interstitial granuloma was also noted. Ziehl-Neelsen stain was negative.
Overall, these features are most suggestive of pleuro-parenchymal sar-
coidosis.
A further trial of combination therapy (hydroxychloroquine (200mg
bd), azathioprine (150mg daily) and prednisolone (10mg)) was at-
tempted, stabilising the parenchymal disease over a 6-month period,
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but was associated with continued pleural ﬂuid accumulation on the
left, in the absence of re-accumulation on the right. The patient was
subsequently referred for left-sided talc pleurodesis with a proposed
plan to seek funding for anti-Tumour Necrosis Factor-α biological
therapy if this failed.
2. Discussion
Sarcoidosis is a multisystem disease characterised by non-caseating
granulomas. Whilst it most frequently aﬀects the lungs and lymph
nodes, extrapulmonary presentations of the skin and eyes are also
common. The diﬀerential diagnosis for nodal calciﬁcation and
Abbreviations used
FEV1 Forced expiratory volume in 1 second
FVC Forced vital capacity
TLCO Transfer factor for carbon monoxide
KCO Transfer coeﬃcient
ECG Electrocardiogram
HRCT High Resolution Computed Tomography
PE Pleural eﬀusion
ACE Angiotensin converting enzyme
MRI Magnetic resonance imaging
Fig. 1. a) CXR and representative HRCT images taken at presentation, 9 months and 21 months and 6 months post right talc pleurodesis. (i) CXR at presentation demonstrates blunting of
the costophrenic angles with scattered peribronchial thickening in the mid and lower zones. (ii) CXR 9 months later following a tapering course of prednisolone therapy and maintenance
of 10mg daily, demonstrating blunting of the costophrenic angles with worsening of the right sided eﬀusion. iii) CXR at 21 months following repeated trials of tapering prednisolone,
attempted diuresis and trial of methotrexate therapy in conjunction with 10mg prednisolone: CXR demonstrates persistent pleural eﬀusions with apparent worsening of both right and left
eﬀusions. iv) CXR 6 months' post pleurodesis on prednisolone 10mg once daily, hydroxychloroquine 200mg twice daily and azathioprine 150mg once daily. No reaccumulation of right
eﬀusion. b) Representative HRCT images taken at presentation and 9 months later: Soft tissue windows above and lung windows below of i) HRCT images taken at presentation
demonstrating mediastinal and hilar nodal calciﬁcation, perilymphatic nodularity and bilateral pleural eﬀusions, left larger than right. ii) Nine months later following a tapering course of
prednisolone therapy and maintenance of 10mg daily. Stable mediastinal and hilar nodal calciﬁcation and perilymphatic nodularity with bilateral pleural eﬀusions, worsening on the
right. iii) Four weeks post right talc-pleurodesis. Worsening nodularity in the context of slight increase of left sided-eﬀusion. iv) Six months after right-talc pleurodesis. Stable appearances
of lung nodularity in the context of worsening left eﬀusion on prednisolone, hydroxychloroquine and azathioprine. c) Histological analysis i) Endobronchial biopsy demonstrates non-
caseating granuloma. ii) Right sided VATS pleural biopsy demonstrating pleural and iii) subpleural based non-caseating granulomatous inﬂammation with surrounding lymphocytic
inﬁltration and accompanying ﬁbrosis. iv) Concurrent VATS lung wedge biopsy demonstrates an additional interstitial sarcoidal granuloma. ZN and Wade-Fite stains were negative
excluding tuberculosis. No malignancy was seen. Scale bar indicates 500 μm.
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parenchymal nodularity in this patient includes sarcoidosis, tubercu-
losis (TB) and occupational lung disease. The perilymphatic distribution
of nodules would be suggestive of sarcoidosis and could account for the
lymph node calciﬁcation. There has been no exposure to TB or silica
making the latter diagnoses less likely.
Pleural involvement is a rare manifestation with variable reported
incidence of eﬀusion on chest radiograph as low as 0.16% in the largest
retrospective cohort analysed to date [1]. Studies using thoracic ultra-
sound, with its superior sensitivity in detecting eﬀusions indicate a
higher incidence of 2.8% [2]. The limited data available from small
case series of sarcoidosis-related pleural eﬀusions (PEs) suggests they
are often exudative and lymphocytic [2], typically with a CD4+/CD8+
ratio between 2.61 and 8.6 [3]. They are also more commonly right-
sided (45%) and less frequently bilateral (22%) [4]. The largest case
series has demonstrated that 60% of PEs in such cases were not related
to sarcoidosis itself [2], and were attributable other processes such as
ischaemic cardiomyopathies or infection. Serum amyloid A, soluble
interleukin-2 receptor (sIL-2R), lysozyme and the glycoprotein KL-6
have all been proposed as potential serum biomarkers for sarcoidosis
but each lacks speciﬁcity and sensitivity for clinical usage and to the
authors knowledge have not been validated in pleural ﬂuid [5]. The
identiﬁcation of pleural eﬀusions (PEs) in this patient therefore
prompted thorough investigation of the aetiology of both the interstitial
lung disease and PEs.
The diﬀerential diagnosis of a lymphocytic PE includes; carcinoma,
TB, lymphoma, chronic heart failure, autoimmune diseases and sar-
coidosis. As the eﬀusion was cytologically negative and CT showed no
evidence of nodular or mediastinal thickening, malignancy was less
likely. It is important to exclude tuberculosis and this was eﬀectively
achieved with normal pleural ADA levels in a Caucasian female.
Lymphoma should also be considered and assessment of ﬂuid lym-
phocyte subsets is useful to exclude this possibility. Finally, as the ef-
fusions were bilateral and lymphocytic, the chances of this being due to
an autoimmune process or heart failure were increased. The patient was
investigated accordingly with autoimmune proﬁle, ECHO and cardiac
MRI.
The signiﬁcant, bilateral pleural involvement at initial presentation
in this case is atypical for pleural sarcoidosis, as is the worsening of
pleural disease control despite immunomodulatory therapy (Fig. 3
[6–15]). The vast majority of sarcoidosis-related PEs reported in the
literature have been small and spontaneously resolve [16], whilst pa-
tients with larger symptomatic eﬀusions have received corticosteroid
therapy alone or in combination with hydroxychloroquine, with a good
response (see Fig. 3) [6–15].
Current paradigms suggest PEs may develop in the context of sar-
coidosis due to inﬂammation of the visceral and parietal pleura sec-
ondary to peripheral lung granulomas [2]. The histology presented in
this case certainly supports this hypothesis. Whilst PEs can occur in any
of the Scadding radiological stages of sarcoidosis [4], there is a ten-
dency to form during acute exacerbations [2]. Suppressing the immune
response should therefore decrease net pleural ﬂuid formation. The
failure to do so is this case either suggests suboptimal control or an
alternative mechanism behind ﬂuid formation.
3. Conclusion
In summary, the presence of a large symptomatic PE in a patient
with sarcoidosis is uncommon and should prompt further investigation
for an alternate aetiology. In refractory cases, such as the one illu-
strated, invasive pleural intervention and immunomodulatory therapies
may be required.
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Fig. 2. Laboratory investigations and pleural
ﬂuid analysis results. Abbreviations: ACE angio-
tensin-converting enzyme, ADA adenosine dea-
minase, NT-Pro-BNP N-terminal pro b-type na-
triuretic peptide.
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Fig. 3. Literature review of small case series and case reports of pleural eﬀusion attributable to sarcoidosis between 2014 and 2017. Abbreviations: PE Pleural eﬀusion, yr year, ADA
adenosine deaminase.
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